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Functionally active plasminogen activator inhibitor 1 (PAl) is bound to a discrete binding protein in plasma [(1988) 
Thromb. Haemost. 59, 392-395]. The binding protein has now been partially purified using conventional chromatograph- 
ic techniques. After addition of active PAl its complex with the binding protein was purified by chromatography on in- 
solubilized monoclonal ntibodies towards PAl. Dodecylsulphate (polyacrylamide g l electrophoresis revealed two main 
compounds with molecular masses of 50 and 75 kDa respectively. Nl-I2-terminal mino acid sequence analysis and immu- 
noblotting analysis uggested that the two compounds were PAl (50 kDa) and vitronectin (75 kDa). We conclude that 
the PAl-binding protein is identical to vitronectin. 
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1. INTRODUCTION 
On gel filtration of functionally active 
plasminogen activator inhibitor 1 (PAI) in the 
presence of human plasma [1] or fetal calf serum 
[2] it behaves as a high molecular mass protein. In 
contrast, functionally inactive or so called 'latent' 
PAl filters as a 50 kDa compound [2,3], in agree- 
ment with its suggested primary structure [4]. 
Recently we presented evidence that the deviating 
gel filtration behaviour of functionally active PAI 
in the presence of plasma/serum is due to the ex- 
istence of a discrete PAl-binding protein in 
plasma/serum [3]. 
In the present work we have purified the com- 
plex between PAI and the binding protein from 
human plasma and then characterized the com- 
pounds by structural and immunochemical 
methods. 
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2. MATERIALS AND METHODS 
2.1. Proteins 
PAl, mostly in a functionally inactive form, was purified 
from conditioned medium from the fibrosarcoma cell-line HT 
1080 by heparin-Sepharose chromatography, gel filtration on 
Sephadex G-150 and chromatography on carboxymethyl 
cellulose. The procedure isdescribed in detail elsewhere [5]. The 
latent PAl was reactivated by treatment with 4 mol/1 
guanidinium chloride at pH 5.5 as described [5]+ Specific ac- 
tivities of about 250000-500000 arbitrary units/mg were 
typically obtained. 
Vitronectin was purified according to a published procedure 
[6]. The monoclonal and polyclonal antibodies towards human 
PAl have been described earlier [7,81. The rabbit antiserum 
towards human vitronectin initially used, was a kind gift from 
Dr Bj6rn Dahlbiick (Dept of Clinical Chemistry, Maim6 
General Hospital, Sweden), but in the published experiments 
another antiserum was used, produced by immunization of a 
rabbit with purified vitronectin. 
2.2. Plasma 
Freshly frozen citrated human plasma was a kind gift from 
the Blood Bank of Karolinska Hospital (courtesy of Dr Olof 
Akerblom). 
2.3. Reagents 
Sephadex, Sepharose derivatives, Sephacryl and DEAE- 
Sephacel were from Pharmacia (Uppsala, Sweden). 
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Acrylamide, SDS, 4-chloro-l-naphthol and nitrocellulose heets 
were from BioRad (Richmond, CA, USA). Horseradish 
peroxidase-conjugated anti-rabbit lgG was obtained from 
Dakopatts (Copenhagen, Denmark). Aprotinin (Trasylol ® ) 
was from Bayer AG (Leverkusen, FRG). 
2.4. Functional and immunological determination fPAl 
PAI activity was measured by the method of Chmielewska 
and Wiman [9] utilizing a commercially available kit (Spec- 
trolyse fibrin, Biopool AB, Ume~, Sweden). One unit of in- 
hibitor was defined as the amount which inhibited one IU of 
one-chain tPA. 
Determination f PAI antigen was performed with a double 
antibody radioimmuoassay as described previously [8]. Purified 
latent PAI from HT 1080 cells was utilized as standard and 
after labelling with 125I as tracer. 
3.2. Purification and analyses of the complex 
between PAl and the PAI-binding protein 
The material obtained from the Blue Sepharose 
column (fig.3) was mixed with an equal (on activity 
basis) amount of reactivated PAI and subjected to 
gel filtration on Sephacryl S-300. The main PAI 
activity peak, eluting as a high molecular mass 
compound together with the main protein peak, 
was further purified by affinity chromatography 
on insolubilized monoclonal antibodies towards 
human PAI. The column was washed with 
0.05 tool/1 sodium phosphate buffer, pH 7.3, con- 
taining 0.1 mol/l NaCl and 0.1 g/l Tween 80. 
2.5. Determination fPAl-binding capacity 
The PAl-binding capacity was routinely determined by mix- 
ing reactivated PAI (500 arb units) with the sample to be tested, 
followed by gel filtration on a Sephadex G-150 column (2 cm ~ 
x 18 cm) equilibrated with 0.05 mol/1 sodium acetate buffer, 
pH 5.5, containing 0.5 mol/l NaCI and 0.1 g Tween 80/1. The 
fractions were tested for PAI activity and the total amount of 
PAl activity in the first peak was used as an estimate of the 
PAI-binding capacity [3]. 
2.6. SDS-polyacrylamide gelelectrophoresis 
Polyacrylamide gel electrophoresis in the presence of SDS 
was performed by an established procedure [10], using a flat 
bed electrophoresis apparatus (Pharmacia, Uppsaia, Sweden). 
Staining was performed by the silver staining procedure [11]. 
Alternatively immunoblotting was performed. The proteins 
were transferred electrophoretically to a nitrocellulose heet us- 
ing a BioRad (Richmond, USA) transblot cell After blocking 
with Tween 20, the nitrocellulose sheet was treated with 
monospecific rabbit anti-human PAI lgG, or rabbit anti-human 
vitronectin IgG preparations and subsequently with horseradish 
peroxidase-labeUed goat anti-rabbit IgG. The development was 
performed with 4-chloro-l-naphthol and H202 [11]. 
2.7. Determination fNHz-terminal mino acid sequences 
This was performed with a pulsed liquid phase sequencer 
(model 477A, Applied Biosystems, Foster City, CA, USA) 
equipped with an on-line PTH 120A analyzer. A standard pro- 
gramme was used and the reagents were provided by the 
manufacturer. 
3. RESULTS 
3.1. Purification of the PAl-binding protein 
A three step procedure was used to partially 
purify the PAI-binding protein from plasma: gel 
filtration on Sephacryl S-300 (fig.l), DEAE- 
cellulose chromatography (fig.2) and Blue 
Sepharose chromatography (fig.3). With this pro- 
cedure the PAI-binding protein was purified about 
170-fold with a yield of about 25°70 (table 1). 
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Fig.l. Gel filtration of human plasma (45 ml) on Sephacryl 
S-300 (20 cm 2 × 75 cm) equilibrated with 0.05 tool/1 sodium 
phosphate buffer, pH 7.0, containing 0.05 tool/1 NaCI and 10 
units aprotinin/ml. The flow rate was 60 ml/h and 10 ml 
fractions were collected. Absorbance at 280 nm (o----o); PAl- 
binding capacity (o---o). 
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Fig.2. DEAE-cellulose chromatography of the pool of PAI- 
binding protein from the S-300 chromatogram in fig.1. The 
column (5 cm 2 x 6 cm) was equilibrated with the same 
phosphate buffer as the S-300 column. Elution was performed 
with a linear gradient (300 ml total volume) to 0.05 mol/l 
sodium phosphate buffer, pH 7.0, containing 0.4 mol/l NaC1 
and 10 units aprotinin/ml. The flow rate was 25 ml/h and 
10 ml fractions were collected. Absorbance at 280 nm (= ~.); 
PAI-binding capacity (o---~). 
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Table 1 
Partial purification of PAl-binding protein, purification factors and yields in the 
different steps 
Step Volume Absorbance PAl-binding Purification Yield 
(ml) at 280 capacity factor (%) 
(U/ml) 
Plasma 45 62 55 000 1 100 
S-300 150 4.9 12000 2.8 73 
DEAE-cellulose 40 0.70 24000 39 39 
Blue Sepharose 10 0.41 62000 170 25 
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Fig.3. The PAl-binding protein peak from the DEAE-cellulose 
chromatography was dialyzed against 0.05 mol/l Tris buffer, 
pH 7.4, containing 0.15 mol/l NaCI, 0.01 mol/l EDTA and 10 
units aprotinin/ml and subsequently applied to a Blue 
Sepharose column (2 cm 2 x I0 cm) equilibrated with the same 
buffer. Elution was performed with this buffer containing 
1.15 mol/l NaC1. The flow rate was 20 ml/h and 5 ml fractions 
were collected. Absorbance at 280 nm (~, ~,); PAI-binding 
capacity (c~--o). 
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Fig.4. SDS-polyacrylamide g l electrophoresis of the purified 
complex between PAl and its binding protein from human 
plasma. The gels (reduced samples, R, and non-reduced 
samples, NR) were stained with silver (a) or used for 
immunoblotting with monospecific antisera towards human 
PAl (b) or human vitronectin (c). 
Subsequently, elution was performed with 3 mol/ l  
KSCN in this buffer. The eluted material was 
dialyzed against the phosphate/NaC1 buffer, pH 
7.3, and then subjected to different analytical pro- 
cedures. SDS-polyacrylamide gel electrophoresis 
(fig.4) displayed two major  bands (after reduction) 
with molecular masses o f  50 and 75 kDa, respec- 
tively. Immunoblott ing using monospecif ic 
polyclonal antisera against PA I  or vitronectin 
demonstrated that the 50 kDa band was PA l  and 
that the75 kDa band was vitronectin (fig.4). Due 
to unknown reasons the vitronectin band is not 
clearly displayed on the silver stained gels prior to 
reduction. However, a clearly visible band slightly 
above 75 kDa is still obtained in the immunoblot  
utilizing anti-vitronectin. 
NH2-terminal amino acid sequence analysis on 
microgram quantities of  the PA l /PA l -b ind ing  
protein complex revealed two parallel sequences: 
Va l /Asp-H is /G ln -H is /G lu -Pro /? -P ro /? -  ? /Lys -  
Tyr /? -Val /? - .  This is in agreement with the known 
amino acid sequence of  PAl :  Val-His-His-Pro- 
Pro-Ser-Tyr-Val- [4] and that of  vitronectin: Asp- 
Gln-Glu-Ser-Cys-Lys-Gly-Arg- [12]. 
4. D ISCUSSION 
We have previously demonstrated that func- 
tionally active PA l  in plasma [1] or from the 
f ibrosarcoma cell-line HT  1080 in the presence of  
fetal calf serum [2] behaves as a high molecular 
mass compound.  Recently we provided gel filtra- 
t ion data indicating that PA l  in plasma is bound to 
what looks like a carrier protein [3]. In the present 
work the binding protein has been partially 
purified from human plasma using conventional 
chromatographic procedures. After addition of  
functionally active PA l  to this material, the com- 
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plex between PA I  and the binding protein was 
purified first by gel filtration and subsequently by 
affinity chromatography on insolubilized 
monoclonal  antibodies towards human PAI .  The 
complex was analyzed by SDS-polyacrylamide gel 
electrophoresis, NH2-terminal amino acid se- 
quence analysis and immunoblott ing. Thus, the 
complex contained two main compounds:  a 
50 kDa compound identical to PA I  and a 75 kDa 
compound identical to vitronectin. 
Recently we also produced data suggesting that 
the high molecular mass PA I  form obtained from 
HT 1080 cells in the presence of  fetal calf serum 
constitutes a complex between PA I  and bovine 
vitronectin [5]. Our data that vitronectin is iden- 
tical to the PAI-binding protein is in agreement 
with recent results f rom Collen and co-workers 
[13]. 
So far, the physiological meaning of  this interac- 
tion is unclear, although a slight stabilization of  
the PA I  activity has been observed [14]. Several 
groups have demonstrated that PA I  is adsorbed to 
the extracellular matrix [15,16]. It remains to be  
elucidated if vitronectin also is involved in that in- 
teraction. 
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